Brief: Sanofi/Lunsekimig: Exploratory Velvet Phase 2B Study Did Not Meet Its Primary Endpoint
07/04/2026 06:08
April 7 (Reuters) - Sanofi SA SASY.PA: LUNSEKIMIG MET PRIMARY AND KEY SECONDARY ENDPOINTS IN PHASE 2 RESPIRATORY STUDIES IN ASTHMA AND CRSWNP EXPLORATORY VELVET PHASE 2B STUDY DID NOT MEET ITS PRIMARY ENDPOINT IN MODERATE-TO-SEVERE ATOPIC DERMATITIS AIRCULES PHASE 2B STUDY ACHIEVES PRIMARY AND KEY SECONDARY ENDPOINTS IN MODERATE-TO-SEVERE ASTHMA LUNSEKIMIG IN CLINICAL DEVELOPMENT IN PERSEPHONE AND THESEUS PHASE 3 STUDIES Source text: ID:nGNEF5MKS Further company coverage: SASY.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes